Newer regimen for drug resistant-tuberculosis: A ray of hope or threatening shadows.
作者信息
Mehta Vibha, Arora Ananya, Bajad Pradeep, Pandey Anubhav, Khanna Arjun
机构信息
Department of Microbiology, Amrita Institute of Medical Sciences and Research, Faridabad, Haryana, India.
Department of Pulmonary Medicine, Amrita Institute of Medical Sciences and Research, Faridabad, Haryana, India E-mail:
出版信息
Lung India. 2025 May 1;42(3):177-178. doi: 10.4103/lungindia.lungindia_495_24. Epub 2025 Apr 29.
Abstract
摘要
相似文献
1
Newer regimen for drug resistant-tuberculosis: A ray of hope or threatening shadows.耐多药结核病的新治疗方案：一线希望还是不祥之兆。
Lung India. 2025 May 1;42(3):177-178. doi: 10.4103/lungindia.lungindia_495_24. Epub 2025 Apr 29.
2
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.柳叶刀呼吸医学委员会：2019 年更新：耐多药和无法治愈结核病的流行病学、发病机制、传播、诊断和管理。
Lancet Respir Med. 2019 Sep;7(9):820-826. doi: 10.1016/S2213-2600(19)30263-2.
3
BPaLM Regimen Against Drug-Resistant Tuberculosis in India: A Need of the Hour.印度抗耐药结核病的BPaLM治疗方案：当务之急
Cureus. 2024 Sep 1;16(9):e68421. doi: 10.7759/cureus.68421. eCollection 2024 Sep.
4
5
[Improvement in image-diagnosis of pulmonary tuberculosis].[肺结核影像诊断的改进]
Kekkaku. 1990 Jan;65(1):52-4.
6
Grade III Severe QT Prolongation in an Indian Male on All-Oral Longer Regimen for Multidrug-Resistant Pulmonary Tuberculosis: World's First Case.一名印度男性在接受全口服长疗程治疗耐多药肺结核时出现III级严重QT间期延长：世界首例病例。
Cureus. 2022 Nov 23;14(11):e31819. doi: 10.7759/cureus.31819. eCollection 2022 Nov.
7
[Not Available].[无可用内容]。
Presse Med. 2017 Mar;46(2 Pt 2):e41-e51. doi: 10.1016/j.lpm.2017.01.016. Epub 2017 Feb 28.
8
Management of complex tuberculosis cases: a focus on drug-resistant tuberculous meningitis.复杂结核病病例的管理：以耐药性结核性脑膜炎为重点。
Expert Rev Anti Infect Ther. 2018 Nov;16(11):813-831. doi: 10.1080/14787210.2018.1540930.
9
Feasibility of a "Salvage Regimen" Using Home-based Intravenous Meropenem Therapy With a Delamanid/Bedaquilline Containing Regimen in the Management of MDR/XDR Pediatric Tuberculosis.在家中使用美罗培南静脉注射疗法联合含地拉曼德/贝达喹啉方案的“挽救方案”用于耐多药/广泛耐药儿童结核病治疗的可行性。
Pediatr Infect Dis J. 2022 May 1;41(5):401-404. doi: 10.1097/INF.0000000000003486.
10
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.评估新批准的耐多药结核病药物（终结结核病）：一项适应性、多国随机对照试验的研究方案
Trials. 2021 Sep 25;22(1):651. doi: 10.1186/s13063-021-05491-3.
本文引用的文献
1
Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis.基因组学诊断贝达喹啉耐药结核病的机遇和限制：系统评价和个体分离物荟萃分析。
Lancet Microbe. 2024 Feb;5(2):e164-e172. doi: 10.1016/S2666-5247(23)00317-8. Epub 2024 Jan 9.
2
Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study.南非开普敦耐多药结核病患者中的贝达喹啉耐药性：一项回顾性纵向队列研究。
Lancet Microbe. 2023 Dec;4(12):e972-e982. doi: 10.1016/S2666-5247(23)00172-6. Epub 2023 Nov 3.
3
Engaging the Private Health Service Delivery Sector for TB Care in India-Miles to Go!让印度私营医疗服务部门参与结核病防治工作——任重道远！
Trop Med Infect Dis. 2023 May 4;8(5):265. doi: 10.3390/tropicalmed8050265.
4
Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in .全基因组测序鉴定与贝达喹啉耐药相关的新型突变体
Front Cell Infect Microbiol. 2022 May 27;12:807095. doi: 10.3389/fcimb.2022.807095. eCollection 2022.
5
Strengthened capacity of India´s bedaquiline Conditional Access Programme for introducing new drugs and regimens.增强印度巴德昔利醇有条件准入方案的能力，以推出新的药物和方案。
Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1067-1072. doi: 10.5588/ijtld.20.0136.
6
Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis.贝达喹啉方案治疗耐多药结核病的临床途径。
S Afr Med J. 2014 Mar;104(3):164-6. doi: 10.7196/samj.7263.
Zotero 插件